The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND Tirzepatide is a dual GLP-1 and gastric inhibitory polypeptide (GIP) receptor agonist whose mechanism of action leads to a greater effect of gastric emptying (GE) than typical Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). After the first dose of tirzepatide, gastric emptying is most substantially delayed. The drug then undergoes tachyphylaxis after subsequent doses. While data on GLP1-RAs has historically demonstrated a lack of impact on bioavailability of oral hormonal contraceptives, manufacturer recommendations for tirzepatide indicate an interaction exists. OBJECTIVES The objectives of this literature review were to review trial data on differences in impact of tirzepatide and GLP-1 RAs on oral hormonal contraceptives as well as provide an analysis of safety data between oral contraceptives and incretin agents. METHODS PubMed and Google Scholar were searched using the generic name for the GLP-1/GIP agent, the generic names for GLP-1 RAs and hormonal contraceptives, followed by the generic names plus the interacting medication. A total of six clinical trials were selected for inclusion in the literature review. RESULTS Of the six articles included in the review, one investigated the use of tirzepatide and showed a statistically significant reduction in AUC, Cmax, and Tmax when tirzepatide was concomitantly administered with an oral hormonal contraceptive. The remaining five studies involving GLP-1 RAs did not show a significant difference of impact of the agents on oral hormonal contraceptives. CONCLUSION In conclusion, it could be suggested that tirzepatide had a greater impact on absorption of oral hormonal contraceptives compared to other GLP-1 RAs. The rapid dose escalation and greater delay on GE enhanced the impact on oral medications such as contraceptives. This differed from other GLP-1 RAs and creates a unique need for enhanced provider and patient education regarding the management of this interaction as well as future studies to evaluate this interaction further.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.443 · Cited by 175
Syed, Y. Y. (2022) · Drugs · doi:10.1007/s40265-022-01746-8 · Cited by 144
Urva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O'Farrell, L., Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14110 · Cited by 143
Nakatani, Y., Maeda, M., Matsumura, M., Shimizu, R., Banba, N., Aso, Y., Yasu, T., & Harasawa, H. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.009 · Cited by 126
Fisman, E. Z., & Tenenbaum, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01412-5 · Cited by 124
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
Jacobsen, L. V., Vouis, J., Hindsberger, C., & Zdravkovic, M. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010389471 · Cited by 41
Kothare, P. A., Seger, M. E., Northrup, J., Mace, K., Mitchell, M. I., & Linnebjerg, H. (2012) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-12-8 · Cited by 35
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Lakhani, M., Kwan, A. T. H., Mihalache, A., Popovic, M. M., Nanji, K., Xie, J. S., Feo, A., Rabinovitch, D., Shor, R., Sadda, S., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.007 · Cited by 70
Gigliotti, L., Warshaw, H., Evert, A., Dawkins, C., Schwartz, J., Susie, C., Kushner, R., Subramanian, S., Handu, D., & Rozga, M. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.10.023 · Cited by 53
Metadata
- Authors
- Skelley, J. W., Swearengin, K., York, A. L., & Glover, L. H.
- Venue
- Journal of the American Pharmacists Association
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 64
- Issue
- 1
- Pages
- 204-211.e4
- ISSN
- 1544-3191 (ISSN-L)
- OpenAlex
- W4388461162
- Cited by
- 66
- References
- 11
- FWCI
- 15.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. https://app.cochat.ai/papers/10.1016/j.japh.2023.10.037
- The paper
- Skelley, J. W., Swearengin, K., York, A. L., & Glover, L. H. (2024). The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. Journal of the American Pharmacists Association. https://doi.org/10.1016/j.japh.2023.10.037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.